CN102762223B - 用于治疗呼吸道病毒性感染的ev576 - Google Patents

用于治疗呼吸道病毒性感染的ev576 Download PDF

Info

Publication number
CN102762223B
CN102762223B CN201180005464.6A CN201180005464A CN102762223B CN 102762223 B CN102762223 B CN 102762223B CN 201180005464 A CN201180005464 A CN 201180005464A CN 102762223 B CN102762223 B CN 102762223B
Authority
CN
China
Prior art keywords
complement
use according
protein
respiratory
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180005464.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102762223A (zh
Inventor
维恩·维斯顿-戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VARLEIGH IMMUNO PHARMACEUTICALS Ltd
Original Assignee
VARLEIGH IMMUNO PHARMACEUTICALS Ltd
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1000318.4A external-priority patent/GB201000318D0/en
Priority claimed from GBGB1005071.4A external-priority patent/GB201005071D0/en
Application filed by VARLEIGH IMMUNO PHARMACEUTICALS Ltd, Volution Immuno Pharmaceuticals SA filed Critical VARLEIGH IMMUNO PHARMACEUTICALS Ltd
Publication of CN102762223A publication Critical patent/CN102762223A/zh
Application granted granted Critical
Publication of CN102762223B publication Critical patent/CN102762223B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180005464.6A 2010-01-08 2011-01-10 用于治疗呼吸道病毒性感染的ev576 Active CN102762223B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1000318.4 2010-01-08
GBGB1000318.4A GB201000318D0 (en) 2010-01-08 2010-01-08 Method of treatment
GB1005071.4 2010-03-25
GBGB1005071.4A GB201005071D0 (en) 2010-03-25 2010-03-25 Method of treatment
PCT/GB2011/000022 WO2011083317A1 (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract

Publications (2)

Publication Number Publication Date
CN102762223A CN102762223A (zh) 2012-10-31
CN102762223B true CN102762223B (zh) 2014-09-03

Family

ID=44305222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180005464.6A Active CN102762223B (zh) 2010-01-08 2011-01-10 用于治疗呼吸道病毒性感染的ev576

Country Status (9)

Country Link
US (4) US20120283167A1 (enExample)
EP (1) EP2521562B1 (enExample)
JP (1) JP5840623B2 (enExample)
CN (1) CN102762223B (enExample)
AU (2) AU2011204483B2 (enExample)
CA (1) CA2785612C (enExample)
NZ (1) NZ601018A (enExample)
PL (1) PL2521562T3 (enExample)
WO (1) WO2011083317A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116785426A (zh) * 2014-03-20 2023-09-22 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
EP4374922A3 (en) 2016-06-14 2024-08-28 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US20220047673A1 (en) * 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
WO2020247610A1 (en) 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN115884764A (zh) * 2020-04-01 2023-03-31 硫创治疗公司 用于治疗乙型冠状病毒感染的半胱胺前体化合物
WO2021226404A1 (en) * 2020-05-08 2021-11-11 Kodiak Sciences Inc. Use of il-6 antibodies and vegf traps, and fusion constructs and conjugates thereof
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098454A2 (en) * 2008-02-05 2009-08-13 Natural Environment Research Council Treatment of diseases and conditions mediated by eicosanoids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3734093A (en) 1992-02-27 1993-09-13 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
MXPA05012880A (es) * 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US7274999B1 (en) * 2006-03-10 2007-09-25 Atmel Corporation Brownout detector system and method
CA2649090A1 (en) * 2006-04-12 2007-10-18 Biocryst Pharmaceuticals, Inc. Intramuscular antiviral treatments
JP2010502687A (ja) * 2006-09-08 2010-01-28 ヴァーレイ・リミテッド 呼吸器疾患の治療方法
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098454A2 (en) * 2008-02-05 2009-08-13 Natural Environment Research Council Treatment of diseases and conditions mediated by eicosanoids

Also Published As

Publication number Publication date
US20200155646A1 (en) 2020-05-21
US20120283167A1 (en) 2012-11-08
JP2013516450A (ja) 2013-05-13
AU2016203058B2 (en) 2018-01-18
EP2521562B1 (en) 2019-09-18
PL2521562T3 (pl) 2020-04-30
US20150196619A1 (en) 2015-07-16
AU2011204483A1 (en) 2012-07-12
US9522171B2 (en) 2016-12-20
US20170065677A1 (en) 2017-03-09
JP5840623B2 (ja) 2016-01-06
CA2785612A1 (en) 2011-07-14
AU2016203058A1 (en) 2016-06-02
CN102762223A (zh) 2012-10-31
NZ601018A (en) 2013-09-27
WO2011083317A1 (en) 2011-07-14
AU2011204483B2 (en) 2016-02-11
EP2521562A1 (en) 2012-11-14
CA2785612C (en) 2019-09-10

Similar Documents

Publication Publication Date Title
CN102762223B (zh) 用于治疗呼吸道病毒性感染的ev576
Tufan et al. COVID-19, immune system response, hyperinflammation and repurposingantirheumatic drugs
Fung et al. Similarities and dissimilarities of COVID-19 and other coronavirus diseases
JP5784078B2 (ja) 呼吸器疾患の治療方法
AU2007293239B2 (en) Method of treating peripheral nerve disorders
CN101340926A (zh) 治疗重症肌无力的方法
CN112717122A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
KR20220167289A (ko) 사이토카인 폭풍 증후군의 치료를 위한 펩타이드
DK2061501T3 (en) METHOD OF TREATING RESPIRATORY DISORDERS
AU2022410688A1 (en) Recombinant protein for treating sars-cov2 disease
HK40043003A (en) Composition comprising a peptide and an inhibitor of viral neuraminidase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: WOLUSHEN YIMIUNUO PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: VARLEIGH IMMUNO PHARMACEUTICALS (VIP) LTD.

Effective date: 20140710

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: British Jersey

Applicant after: Vanessa immune drugs (VIP) Co.,Ltd.

Address before: British Jersey

Applicant before: Volution Immuno Pharmaceuticals S.A.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: VARLEIGH IMMUNO PHARMACEUTICALS LTD. TO: VARLEIGH IMMUNO PHARMACEUTICALS (VIP) LTD.

TA01 Transfer of patent application right

Effective date of registration: 20140710

Address after: Geneva, Switzerland

Applicant after: VARLEIGH IMMUNO PHARMACEUTICALS LTD.

Address before: British Jersey

Applicant before: Vanessa immune drugs (VIP) Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant